Edit |   |
---|---|
Antigenic Specificity | CD152, Human (Tremelimumab biosimilar) |
Clone | Tremelimumab |
Host Species | Recombinant |
Reactive Species | human |
Isotype | IgG2 kappa |
Format | purified |
Size | 1mg, 5mg |
Concentration | 1mg/ml |
Applications | IF, IP, Neut, FuncS, ELISA |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Anti-Human CD152 Recombinant Antibody (Tremelimumab). Tremelimumab (formerly ticilimumab, CP-675, 206) is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Previously in development by Pfizer, it is now in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca. It has been undergoing human trials for the treatment of various cancers but has not attained approval for any. |
Immunogen | n/a |
Other Names | Anti-CD152 Recombinant Antibody, Research Grade Tremelimumab, Anti-Human CD152 Recombinant Antibody(Tremelimumab), CP-675, CP-675, 206, Antibody Drug Analogues, Monoclonal Antibody, YR1160, Research Grade Biosimilars, Biosimilar Antibody |
Gene, Accession # | CAS: 745013-59-6 |
Catalog # | YR1160 |
Price | please inquire |
Order / More Info | CD152, Human (Tremelimumab biosimilar) Antibody from KMD BIOSCIENCE CO. LTD. |
Product Specific References | n/a |